InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches fIVE Calculator. Initially, fIVE DB (from In Vitro Experiments DataBase) is an InSysBio project for in vitro experiments information collection and processing. fIVE DB is designed for QSP modelers and scientists who deal with in vitro/ex vivo data analysis to simplify their hard work and avoid potential errors. Information collected in the database enables them to save time typically spent for gathering and processing of literature and available data.
Now InSysBio presents public beta release of fIVE Calculator which is a web application designed to automatically calculate kinetic parameters from in vitro experiments for modeling of biosystems. The Calculator contains the input fields for the details of in vitro experiments, measurement units and uncertainties. Time- and dose-dependent datasets allows yielding kbase/kmax and Emax/EC50 correspondingly.
Graphical representation helps to visualize the input data and highlights the points picked up by the user for parameters estimation. Parameters are calculated automatically and then displayed in the results table.
Alexander Stepanov, the developer of the Calculator comments on it, “Here we present Shiny application to demonstrate the features of the framework built-in in fIVE DB as well as to provide a possibility to estimate parameters without fitting from available in vitro experiments”.
fIVE Calculator available at https://step-by-step.shinyapps.io/five-db-calculator/
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | July 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
1.
14 Jul 2017 18:49
To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created
Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
1.
25 Jul 2017 13:50
InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc.
Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
2.
25 Jul 2017 17:37
InSysBio will present at the American Conference on Pharmacometrics (ACoP8)!
Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
